Suppr超能文献

氧化应激测量在慢性淋巴细胞白血病中的预后相关性。

Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia.

机构信息

Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.

Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.

出版信息

Eur J Haematol. 2017 Oct;99(4):306-314. doi: 10.1111/ejh.12918. Epub 2017 Aug 3.

Abstract

OBJECTIVE

To evaluate the prognostic significance of oxidative stress (OS) and antioxidant defence status measurement in patients with chronic lymphocytic leukaemia (CLL).

METHODS

d-ROMs test and BAP test were evaluated at diagnosis of 165 patients with CLL and correlated with clinical-biological features and prognosis.

RESULTS

An increased oxidative damage (d-ROMs test) and a reduced antioxidant potential (BAP test) were found in CLL patients than normal controls (P<.0001). CLL patients with higher d-ROMs values had higher number of circulating white blood cells and lymphocytes, and higher values of β -microglobulin. Higher d-ROMs values were found in female (P=.0003), in patients with unmutated IgVH (P=.04), unfavourable cytogenetics (P=.002) and more advanced clinical stage (P=.002). Higher BAP test values were found in patients expressing CD49d (P=.01) and with more advanced clinical stage (P=.004). At a median follow-up of 48 months, CLL patients with d-ROMs ≥418 CARR U were found to have a shorter time to first treatment (TFT) (P=.0002), and a reduced survival (P=.006) than others. CLL patients with BAP test values ≥2155 μmol/L had a shorter TFT (P=.008) and a shorter survival (P=.003).

CONCLUSIONS

OS can affect CLL patients by concomitantly increasing reactive oxygen metabolites production and decreasing antioxidant defences.

摘要

目的

评估慢性淋巴细胞白血病(CLL)患者氧化应激(OS)和抗氧化防御状态测量的预后意义。

方法

在 165 例 CLL 患者诊断时评估 d-ROMs 试验和 BAP 试验,并将其与临床生物学特征和预后相关联。

结果

与正常对照组相比,CLL 患者的氧化损伤(d-ROMs 试验)增加,抗氧化能力降低(BAP 试验)(P<.0001)。d-ROMs 值较高的 CLL 患者循环白细胞和淋巴细胞数量较多,β-微球蛋白值较高。d-ROMs 值较高的患者为女性(P=.0003)、免疫球蛋白重链可变区(IgVH)未突变(P=.04)、不良细胞遗传学(P=.002)和更晚期的临床分期(P=.002)。表达 CD49d 的患者(P=.01)和更晚期的临床分期(P=.004)的患者的 BAP 试验值较高。在中位随访 48 个月时,d-ROMs≥418 CARR U 的 CLL 患者首次治疗(TFT)时间更短(P=.0002),生存时间更短(P=.006)。BAP 试验值≥2155 μmol/L 的 CLL 患者 TFT 更短(P=.008),生存时间更短(P=.003)。

结论

OS 可通过同时增加活性氧代谢物的产生和降低抗氧化防御来影响 CLL 患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验